Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001689
Publisher
BMJ
Online
2020-12-24
DOI
10.1136/jitc-2020-001689
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma
- (2020) S. S. Jeske et al. Immunity & Ageing
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients
- (2019) Carla Fernanda Furtado Gardani et al. Purinergic Signalling
- The Immune System Computes the State of the Body: Crowd Wisdom, Machine Learning, and Immune Cell Reference Repertoires Help Manage Inflammation
- (2019) Irun R. Cohen et al. Frontiers in Immunology
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1
- (2019) María de Lourdes Mora-García et al. MEDIATORS OF INFLAMMATION
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
- (2019) Said A. Goueli et al. PLoS One
- Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
- (2018) Tao Jiang et al. BMC CANCER
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
- (2018) Curtis H. Kugel et al. CLINICAL CANCER RESEARCH
- CD73 expression and clinical significance in human metastatic melanoma
- (2018) Inês Monteiro et al. Oncotarget
- The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
- (2018) Ping Li et al. OncoTargets and Therapy
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- (2017) Silvana Morello et al. Journal of Translational Medicine
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Abstract 1538: Levels and enzyme activity of CD73 in primary samples from cancer patients
- (2015) Qihui Huang et al. CANCER RESEARCH
- A novel hypothesis for an alkaline phosphatase ‘rescue’ mechanism in the hepatic acute phase immune response
- (2013) Adrianne F. Pike et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
- (2013) Alberto L Horenstein et al. OncoImmunology
- NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
- (2012) H Wang et al. BRITISH JOURNAL OF CANCER
- Cellular function and molecular structure of ecto-nucleotidases
- (2012) Herbert Zimmermann et al. Purinergic Signalling
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
- (2008) Gennady G. Yegutkin BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started